Drug information on Nourubin (Daunorubicin) from Cadila Pharmaceuticals Ltd.

Medical Condition(s) for which Nourubin may be prescribed

---

•   Skin : Rash, skin inflammation and hives.

•   Gastrointestinal : Nausea, vomiting, diarrhea and abdominal pain.

•   Local : Cell death and painful induration.

•   Miscellaneous : Fever, chills and rarely allergic reactions.

IV- Adult- The recommended dose is 60 – 75mg/m²/day BSA (body surface area), every 3 weeks.

It comes as a solution for injection to be administered by a healthcare provider into the vein.

Contraindicated in patients with heart disease and hypersensitivity.

• Caution should be exercised in patients with heart, kidney or liver disease, bone marrow depression, gout, any allergy, who are taking other medications, children, during pregnancy and breastfeeding.

• Patient may develop with increased risk of heart disease (myocardial toxicity), bone marrow depression and secondary malignancy (cancer); if it is so consult with your doctor immediately.

• It may reduce platelet counts, which leads to bleeding; avoid injury or bruising.

• Monitor complete blood cell counts, heart, liver and kidney functions regularly while taking this medication.

• Avoid contact with people with infections.

Avoid drinking alcoholic beverages.
Avoid excess dosage.

Injection: Store it in refrigerator (2-8°C). Do not freeze.
Powder for injection: Store it at controlled room temperature (15-25°C).

Schedule : G  Drugs that are to be used only under medical supervision.